Jazz Pharmaceuticals (JAZZ) 172.14 $JAZZ
Market Activity, Drug Approval, Upcoming Conference, and Presentation of Clinical Data - Research Reports on Jazz, Keryx, Vertex, WellPoint and GSK
PR Newswire - Wed Sep 10, 8:15AM CDT
Today, Analysts Review released its research reports regarding Jazz Pharmaceuticals plc (NASDAQ: JAZZ), Keryx Biopharmaceuticals (NASDAQ: KERX), Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), WellPoint Inc. (NYSE: WLP) and GlaxoSmithKline plc (NYSE: GSK). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6356-100free.
Jazz Pharmaceuticals Rises 1.68% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Mon Sep 08, 4:17PM CDT
Jazz Pharmaceuticals (NASDAQ:JAZZ) traded in a range yesterday that spanned from a low of $166.00 to a high of $171.72. Yesterday, the shares gained 1.7%, which took the trading range above the 3-day high of $168.88 on volume of 1.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Jazz Pharmaceuticals (JAZZ) in Focus: Stock Rises 7.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Sep 08, 7:44AM CDT
Jazz Pharmaceuticals (JAZZ) was a big mover last session, as the company saw its shares rise a little over 7% on the day
Stocks Reverse Higher, But Some Retailers Sell Off
at Investor's Business Daily - Fri Sep 05, 3:15PM CDT
The stock market closed higher and at session highs after erasing morning losses. The positive reversal was the opposite of the previous two days, when indexes made negative price reversals. The Nasdaq and the S&P 500 climbed 0.5% Friday; the Dow...
Stocks Rise, Turn Positive Going Into Final Hour
at Investor's Business Daily - Fri Sep 05, 2:16PM CDT
Stocks advanced off lows of the day Friday going into the last hour of trading, looking to finish the week with the major indexes up. The Nasdaq and the Dow Jones industrial average rose 0.2% and the S&P 500 was up 3%. Volume was running slightly...
Jazz Pharmaceuticals Shares Up 6.3% Since SmarTrend's Buy Recommendation (JAZZ)
Comtex SmarTrend(R) - Thu Sep 04, 5:00PM CDT
SmarTrend identified an Uptrend for Jazz Pharmaceuticals (NASDAQ:JAZZ) on August 15th, 2014 at $147.63. In approximately 3 weeks, Jazz Pharmaceuticals has returned 6.26% as of today's recent price of $156.87.
Jazz Pharmaceuticals Falls 4.17% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Thu Sep 04, 4:16PM CDT
Jazz Pharmaceuticals (NASDAQ:JAZZ) traded in a range yesterday that spanned from a low of $156.51 to a high of $163.34. Yesterday, the shares fell 4.2%, which took the trading range below the 3-day low of $160.49 on volume of 1.2 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Three Stocks Top-Performing Funds Like: Facebook Baidu Gilead
at Investor's Business Daily - Wed Sep 03, 5:28PM CDT
The new buys list of top-performing funds the past three months showed some heavy buying of top-rated stocks. The nation's leading funds have been stocking up on medical issues, which fared well as the market resumed its uptrend in August. Large...
Positive Drug Results, Market Activity Updates, Sustainability Report, Acquisitions, and Plant Closure - Research Reports on Repros, Jazz, Ingersoll-Rand, Nokia and Duke Energy
PR Newswire - Tue Sep 02, 8:10AM CDT
Today, Analysts Review released its research reports regarding Repros Therapeutics Inc. (NASDAQ: RPRX), Jazz Pharmaceuticals Plc (NASDAQ: JAZZ), Ingersoll-Rand Plc (NYSE: IR), Nokia Corporation (NYSE: NOK) and Duke Energy Corporation (NYSE: DUK). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6149-100free.
Baidu, AerCap And Jazz Among Basing Top World Stocks
at Investor's Business Daily - Fri Aug 29, 5:49PM CDT
It was a mixed week for global markets, with stocks in the U.S. and Europe posting notable gains while the top indexes in China ceded ground. Stocks on IBD's Top 10 World Stocks list nearly all gained, some significantly, while others held beneath...
Health Care Sector Stocks on our Radar -- Pacific Biosciences of California, Thermo Fisher Scientific, Lexicon Pharma, Vical, and Jazz Pharma
PR Newswire - Wed Aug 27, 7:50AM CDT
On Tuesday, August 26, 2014, the NASDAQ Composite ended at 4,570.64, up 0.29%, the Dow Jones Industrial Average finished the day 0.17% higher at 17,106.70, and the S&P 500 closed at 2,000.02, up 0.11%. The gains were broad based as seven out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 735.62, up 0.41%, and the index has advanced 7.97% in the last three months. Investor-Edge has initiated coverage on the following equities: Pacific Biosciences of California Inc. (NASDAQ: PACB), Thermo Fisher Scientific Inc. (NYSE: TMO), Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX), Vical Inc. (NASDAQ: VICL), and Jazz Pharmaceuticals PLC (NASDAQ: JAZZ). Free research on these five companies can be accessed at:
Gilead, Jazz Among 4 Top Big Cap Medicals To Watch
at Investor's Business Daily - Wed Aug 27, 7:02AM CDT
Today's Screen of the Day features four institutional-quality drug and medical Big Caps stocks with solid fundamentals. Jazz Pharmaceuticals (JAZZ), which has a market cap of $9.85 billion, earned an IBD Composite Rating of 99, which means that it...
SmarTrend Watching for Potential Pullback in Shares of Jazz Pharmaceuticals After 1.30% Gain
Comtex SmarTrend(R) - Mon Aug 25, 5:02PM CDT
Jazz Pharmaceuticals (NASDAQ:JAZZ) traded in a range yesterday that spanned from a low of $159.23 to a high of $162.80. Yesterday, the shares gained 1.3%, which took the trading range above the 3-day high of $161.25 on volume of 671,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
OpportunityAnalyzer: Graft-Versus-Host Disease - Opportunity Analysis and Forecasts to 2018
M2 - Mon Aug 25, 10:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hb86nm/opportunityanalyze) has announced the addition of the "OpportunityAnalyzer: Graft-Versus-Host Disease - Opportunity Analysis and Forecasts to 2018" report to their offering. New Drugs to Boost Graft-Versus-Host Disease Treatment Market by 2018 The graft-versus-host disease (GVHD) treatment market value will increase from $297 million in 2013 to $407 million by 2018, at a Compound Annual Growth Rate (CAGR) of 6.59%, according to research and consulting firm The authors. This report provides annualized graft-versus-host disease therapeutics market revenue, cost of therapies and forecasts from 2013 to 2018 across six major markets: the US, France, Germany, Italy, Spain and the UK. Key topics covered include strategic product assessment, market characterization, unmet needs, research and development strategies, clinical trial design, pipeline analysis and competitor evaluations. The report states that this growth, which will occur over six major markets (6MM: the US, France, Germany, Italy, Spain and the UK), will be strongest in the five European countries (5EU), where multiple product launches will accelerate the market value at a CAGR of 9.26% during the forecast period. Eirini Vavatsikou, Ph.D., The authors's Analyst covering Immunology, says: Several products are due to enter the GVHD market by 2018, with Osiris Therapeutics and Mesoblast's first-to-market Prochymal expected to generate sales of $12.2 million in 2018. Dr. Falk Pharma's Budenofalk is forecast to enter the European GVHD market in 2016, while ATG-Fresenius (ATG-F) will arrive in the US market in 2017. These two products are estimated to achieve 2018 sales of $11,900 and $8 million, respectively. The authors forecasts that both Jazz Pharmaceuticals' Leukotac and Adienne Pharma's Begedina will enter the GVHD market in 2018, with Leukotac being launched only in the 5EU. Due to their anticipated premium pricing, these drugs are expected to add over $18 million to the 6MM sales by the end of 2018. While multiple biologic products will fall off their respective patent cliffs by the end of the forecast period, Vavatsikou states that this will not impact the GVHD forecast for two important reasons. The analyst explains: Firstly, biosimilar versions of prominent off-label GVHD biologics, such as Rituxan and Campath/Lemtrada, are in very early development and are yet to succeed in clinical trials. Secondly, hematologists across the 6MM are not expected to use biosimilar versions of branded biologics in GVHD patients whose health is already severely compromised. Furthermore, key opinion leaders interviewed by The authors unanimously agreed that they would prefer new biosimilars to be tested in a GVHD clinical trial setting before they use such treatments in the clinic. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 4 Epidemiology 5 Current Treatment Options 6 Unmet Need and Opportunity 7 Research and Development Strategies 8 Pipeline Assessment 9 Pipeline and Off-Label Valuation Analysis 10 Appendix For more information visit http://www.researchandmarkets.com/research/hb...ityanalyze
Jazz Pharmaceuticals Earnings Hindsight: Up 17.0% in Last 20 Days (JAZZ)
Comtex SmarTrend(R) - Mon Aug 25, 7:29AM CDT
When Jazz Pharmaceuticals (NASDAQ:JAZZ) reported earnings two weeks ago on August 5th, 2014, analysts, on average, expected the company to report earnings of $1.92 on sales of $273.2 million. Jazz Pharmaceuticals actually reported earnings of $2.05 per share on sales of $291.2 million, beating EPS estimates by $0.13 and beating revenue estimates by $18.0 million. Since the company's report, shares of Jazz Pharmaceuticals have risen from $135.80 to $158.83, representing a gain of 17.0% in the past 20 days.
Jazz Pharmaceuticals (JAZZ) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Aug 21, 8:06AM CDT
Jazz Pharmaceuticals (JAZZ) Shares March Higher, Can It Continue?
Appointments, Market Activity, Regulatory Approvals, and Rights Acquisition - Research Reports on Nike, Morgan Stanley, Regeneron, Zimmer and Jazz
PR Newswire - Thu Aug 21, 8:00AM CDT
Today, Analysts Review released its research reports regarding Nike, Inc. (NYSE: NKE), Morgan Stanley (NYSE: MS), Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), Zimmer Holdings, Inc. (NYSE: ZMH) and Jazz Pharmaceuticals plc (NASDAQ: JAZZ). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5880-100free.
Major Indexes Turn Mixed; Jazz Pharmaceuticals Turns Up
at Investor's Business Daily - Wed Aug 20, 12:11PM CDT
Stocks have turned mixed after lingering in mildly lower territory early on. Thanks to Home Depot (HD) and Boeing (BA), the Dow Jones industrial average rose 0.2%. The S&P 500 edged up 0.1% after falling 0.2%. Meanwhile, the Nasdaq was near the flat...
Box Powers Cloud Collaboration for Leading Life Sciences Organizations
Business Wire - Wed Aug 20, 11:00AM CDT
Box today announced that leading pharmaceutical and life sciences organizations Jazz Pharmaceuticals and Boston Scientific Corporation have recently chosen Box as their primary platform for managing and collaborating on content. These companies join Box's growing pharmaceutical and life sciences customer base, which includes AstraZeneca, Eli Lilly and Company, Edwards Lifesciences and others.
SmarTrend Watching for Potential Pullback in Shares of Jazz Pharmaceuticals After 2.86% Gain
Comtex SmarTrend(R) - Tue Aug 19, 4:19PM CDT
Jazz Pharmaceuticals (NASDAQ:JAZZ) traded in a range yesterday that spanned from a low of $153.07 to a high of $159.50. Yesterday, the shares gained 2.9%, which took the trading range above the 3-day high of $152.69 on volume of 1.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Market Activity, Drug Approval, Upcoming Conference, and Presentation of Clinical Data - Research Reports on Jazz, Keryx, Vertex, WellPoint and GSK
PR Newswire - Wed Sep 10, 8:15AM CDT
Today, Analysts Review released its research reports regarding Jazz Pharmaceuticals plc (NASDAQ: JAZZ), Keryx Biopharmaceuticals (NASDAQ: KERX), Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), WellPoint Inc. (NYSE: WLP) and GlaxoSmithKline plc (NYSE: GSK). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6356-100free.
Jazz Pharmaceuticals Rises 1.68% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Mon Sep 08, 4:17PM CDT
Jazz Pharmaceuticals (NASDAQ:JAZZ) traded in a range yesterday that spanned from a low of $166.00 to a high of $171.72. Yesterday, the shares gained 1.7%, which took the trading range above the 3-day high of $168.88 on volume of 1.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Jazz Pharmaceuticals (JAZZ) in Focus: Stock Rises 7.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Sep 08, 7:44AM CDT
Jazz Pharmaceuticals (JAZZ) was a big mover last session, as the company saw its shares rise a little over 7% on the day
Stocks Reverse Higher, But Some Retailers Sell Off
at Investor's Business Daily - Fri Sep 05, 3:15PM CDT
The stock market closed higher and at session highs after erasing morning losses. The positive reversal was the opposite of the previous two days, when indexes made negative price reversals. The Nasdaq and the S&P 500 climbed 0.5% Friday; the Dow...
Stocks Rise, Turn Positive Going Into Final Hour
at Investor's Business Daily - Fri Sep 05, 2:16PM CDT
Stocks advanced off lows of the day Friday going into the last hour of trading, looking to finish the week with the major indexes up. The Nasdaq and the Dow Jones industrial average rose 0.2% and the S&P 500 was up 3%. Volume was running slightly...
Jazz Pharmaceuticals Shares Up 6.3% Since SmarTrend's Buy Recommendation (JAZZ)
Comtex SmarTrend(R) - Thu Sep 04, 5:00PM CDT
SmarTrend identified an Uptrend for Jazz Pharmaceuticals (NASDAQ:JAZZ) on August 15th, 2014 at $147.63. In approximately 3 weeks, Jazz Pharmaceuticals has returned 6.26% as of today's recent price of $156.87.
Jazz Pharmaceuticals Falls 4.17% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Thu Sep 04, 4:16PM CDT
Jazz Pharmaceuticals (NASDAQ:JAZZ) traded in a range yesterday that spanned from a low of $156.51 to a high of $163.34. Yesterday, the shares fell 4.2%, which took the trading range below the 3-day low of $160.49 on volume of 1.2 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Three Stocks Top-Performing Funds Like: Facebook Baidu Gilead
at Investor's Business Daily - Wed Sep 03, 5:28PM CDT
The new buys list of top-performing funds the past three months showed some heavy buying of top-rated stocks. The nation's leading funds have been stocking up on medical issues, which fared well as the market resumed its uptrend in August. Large...
Positive Drug Results, Market Activity Updates, Sustainability Report, Acquisitions, and Plant Closure - Research Reports on Repros, Jazz, Ingersoll-Rand, Nokia and Duke Energy
PR Newswire - Tue Sep 02, 8:10AM CDT
Today, Analysts Review released its research reports regarding Repros Therapeutics Inc. (NASDAQ: RPRX), Jazz Pharmaceuticals Plc (NASDAQ: JAZZ), Ingersoll-Rand Plc (NYSE: IR), Nokia Corporation (NYSE: NOK) and Duke Energy Corporation (NYSE: DUK). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6149-100free.
Baidu, AerCap And Jazz Among Basing Top World Stocks
at Investor's Business Daily - Fri Aug 29, 5:49PM CDT
It was a mixed week for global markets, with stocks in the U.S. and Europe posting notable gains while the top indexes in China ceded ground. Stocks on IBD's Top 10 World Stocks list nearly all gained, some significantly, while others held beneath...
Health Care Sector Stocks on our Radar -- Pacific Biosciences of California, Thermo Fisher Scientific, Lexicon Pharma, Vical, and Jazz Pharma
PR Newswire - Wed Aug 27, 7:50AM CDT
On Tuesday, August 26, 2014, the NASDAQ Composite ended at 4,570.64, up 0.29%, the Dow Jones Industrial Average finished the day 0.17% higher at 17,106.70, and the S&P 500 closed at 2,000.02, up 0.11%. The gains were broad based as seven out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 735.62, up 0.41%, and the index has advanced 7.97% in the last three months. Investor-Edge has initiated coverage on the following equities: Pacific Biosciences of California Inc. (NASDAQ: PACB), Thermo Fisher Scientific Inc. (NYSE: TMO), Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX), Vical Inc. (NASDAQ: VICL), and Jazz Pharmaceuticals PLC (NASDAQ: JAZZ). Free research on these five companies can be accessed at:
Gilead, Jazz Among 4 Top Big Cap Medicals To Watch
at Investor's Business Daily - Wed Aug 27, 7:02AM CDT
Today's Screen of the Day features four institutional-quality drug and medical Big Caps stocks with solid fundamentals. Jazz Pharmaceuticals (JAZZ), which has a market cap of $9.85 billion, earned an IBD Composite Rating of 99, which means that it...
SmarTrend Watching for Potential Pullback in Shares of Jazz Pharmaceuticals After 1.30% Gain
Comtex SmarTrend(R) - Mon Aug 25, 5:02PM CDT
Jazz Pharmaceuticals (NASDAQ:JAZZ) traded in a range yesterday that spanned from a low of $159.23 to a high of $162.80. Yesterday, the shares gained 1.3%, which took the trading range above the 3-day high of $161.25 on volume of 671,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
OpportunityAnalyzer: Graft-Versus-Host Disease - Opportunity Analysis and Forecasts to 2018
M2 - Mon Aug 25, 10:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hb86nm/opportunityanalyze) has announced the addition of the "OpportunityAnalyzer: Graft-Versus-Host Disease - Opportunity Analysis and Forecasts to 2018" report to their offering. New Drugs to Boost Graft-Versus-Host Disease Treatment Market by 2018 The graft-versus-host disease (GVHD) treatment market value will increase from $297 million in 2013 to $407 million by 2018, at a Compound Annual Growth Rate (CAGR) of 6.59%, according to research and consulting firm The authors. This report provides annualized graft-versus-host disease therapeutics market revenue, cost of therapies and forecasts from 2013 to 2018 across six major markets: the US, France, Germany, Italy, Spain and the UK. Key topics covered include strategic product assessment, market characterization, unmet needs, research and development strategies, clinical trial design, pipeline analysis and competitor evaluations. The report states that this growth, which will occur over six major markets (6MM: the US, France, Germany, Italy, Spain and the UK), will be strongest in the five European countries (5EU), where multiple product launches will accelerate the market value at a CAGR of 9.26% during the forecast period. Eirini Vavatsikou, Ph.D., The authors's Analyst covering Immunology, says: Several products are due to enter the GVHD market by 2018, with Osiris Therapeutics and Mesoblast's first-to-market Prochymal expected to generate sales of $12.2 million in 2018. Dr. Falk Pharma's Budenofalk is forecast to enter the European GVHD market in 2016, while ATG-Fresenius (ATG-F) will arrive in the US market in 2017. These two products are estimated to achieve 2018 sales of $11,900 and $8 million, respectively. The authors forecasts that both Jazz Pharmaceuticals' Leukotac and Adienne Pharma's Begedina will enter the GVHD market in 2018, with Leukotac being launched only in the 5EU. Due to their anticipated premium pricing, these drugs are expected to add over $18 million to the 6MM sales by the end of 2018. While multiple biologic products will fall off their respective patent cliffs by the end of the forecast period, Vavatsikou states that this will not impact the GVHD forecast for two important reasons. The analyst explains: Firstly, biosimilar versions of prominent off-label GVHD biologics, such as Rituxan and Campath/Lemtrada, are in very early development and are yet to succeed in clinical trials. Secondly, hematologists across the 6MM are not expected to use biosimilar versions of branded biologics in GVHD patients whose health is already severely compromised. Furthermore, key opinion leaders interviewed by The authors unanimously agreed that they would prefer new biosimilars to be tested in a GVHD clinical trial setting before they use such treatments in the clinic. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 4 Epidemiology 5 Current Treatment Options 6 Unmet Need and Opportunity 7 Research and Development Strategies 8 Pipeline Assessment 9 Pipeline and Off-Label Valuation Analysis 10 Appendix For more information visit http://www.researchandmarkets.com/research/hb...ityanalyze
Jazz Pharmaceuticals Earnings Hindsight: Up 17.0% in Last 20 Days (JAZZ)
Comtex SmarTrend(R) - Mon Aug 25, 7:29AM CDT
When Jazz Pharmaceuticals (NASDAQ:JAZZ) reported earnings two weeks ago on August 5th, 2014, analysts, on average, expected the company to report earnings of $1.92 on sales of $273.2 million. Jazz Pharmaceuticals actually reported earnings of $2.05 per share on sales of $291.2 million, beating EPS estimates by $0.13 and beating revenue estimates by $18.0 million. Since the company's report, shares of Jazz Pharmaceuticals have risen from $135.80 to $158.83, representing a gain of 17.0% in the past 20 days.
Jazz Pharmaceuticals (JAZZ) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Aug 21, 8:06AM CDT
Jazz Pharmaceuticals (JAZZ) Shares March Higher, Can It Continue?
Appointments, Market Activity, Regulatory Approvals, and Rights Acquisition - Research Reports on Nike, Morgan Stanley, Regeneron, Zimmer and Jazz
PR Newswire - Thu Aug 21, 8:00AM CDT
Today, Analysts Review released its research reports regarding Nike, Inc. (NYSE: NKE), Morgan Stanley (NYSE: MS), Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), Zimmer Holdings, Inc. (NYSE: ZMH) and Jazz Pharmaceuticals plc (NASDAQ: JAZZ). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5880-100free.
Major Indexes Turn Mixed; Jazz Pharmaceuticals Turns Up
at Investor's Business Daily - Wed Aug 20, 12:11PM CDT
Stocks have turned mixed after lingering in mildly lower territory early on. Thanks to Home Depot (HD) and Boeing (BA), the Dow Jones industrial average rose 0.2%. The S&P 500 edged up 0.1% after falling 0.2%. Meanwhile, the Nasdaq was near the flat...
Box Powers Cloud Collaboration for Leading Life Sciences Organizations
Business Wire - Wed Aug 20, 11:00AM CDT
Box today announced that leading pharmaceutical and life sciences organizations Jazz Pharmaceuticals and Boston Scientific Corporation have recently chosen Box as their primary platform for managing and collaborating on content. These companies join Box's growing pharmaceutical and life sciences customer base, which includes AstraZeneca, Eli Lilly and Company, Edwards Lifesciences and others.
SmarTrend Watching for Potential Pullback in Shares of Jazz Pharmaceuticals After 2.86% Gain
Comtex SmarTrend(R) - Tue Aug 19, 4:19PM CDT
Jazz Pharmaceuticals (NASDAQ:JAZZ) traded in a range yesterday that spanned from a low of $153.07 to a high of $159.50. Yesterday, the shares gained 2.9%, which took the trading range above the 3-day high of $152.69 on volume of 1.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
